in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Asahi Glass to Double Production Capacity for Tafluprost API
3:42 AM MDT | May 15, 2012 | Deepti Ramesh
Asahi Glass (Tokyo) says it has decided to invest about ¥800 million ($10 million) to build a new production line for Tafluprost, an active pharmaceutical ingredient (API) for glaucoma treatment, at the production site of the company’s AGC Wakasa Chemicals (Obama, Fukui Prefecture, Japan) subsidiary. AGC Wakasa Chemicals is wholly owned by Asahi Glass, and it manufactures pharmaceutical and agchem intermediates and active ingredients. The new Tafluprost production line is expected to become operational by March 2013, and it will nearly double Asahi...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee